dc.contributor | Feld, J.J., Toronto Centre for Liver Disease, McLaughlin-Rotman Centre for Global HealthToronto, ON, Canada, Toronto Western Hospital Liver Centre, McLaughlin-Rotman Centre for Global Health, 399 Bathurst StreetToronto, ON, Canada; Jacobson, I.M., Center for the Study of Hepatitis C, Weill Cornell Medical CollegeNew York, NY, United States; Jensen, D.M., Center for Liver Diseases, University of Chicago HospitalsChicago, IL, United States; Foster, G.R., Queen Mary, University of London, Institute of Cellular and Molecular SciencesLondon, United Kingdom; Pol, S., Hopital Cochin, University Paris Descartes and INSERM U1610Paris, France; Tam, E., LAIR CentreVancouver, BC, Canada; Jablkowski, M., Medical University of LodzLodz, Poland; Berak, H., Hospital of Infectious DiseasesWarsaw, Poland; Vierling, J.M., Baylor College of MedicineHouston, TX, United States; Yoshida, E.M., University of British ColumbiaVancouver, BC, Canada; Perez-Gomez, H.R., Hospital Civil de Guadalajara, Instituto de Patologia Infecciosa, Universidad de GuadalajaraGuadalajara, Mexico; Scalori, A., Roche Products LtdWelwyn, United Kingdom; Hooper, G.J., Roche Products LtdWelwyn, United Kingdom; Tavel, J.A., GenentechSouth San Francisco, CA, United States; Navarro, M.T., GenentechSouth San Francisco, CA, United States; Shahdad, S., Roche Products LtdWelwyn, United Kingdom; Kulkarni, R., GenentechSouth San Francisco, CA, United States; Pogam, S.L., Hoffmann-La Roche IncNutley, NJ, United States; Nájera, I., F. Hoffmann-La Roche LtdBasel, Switzerland; Eng, S., GenentechSouth San Francisco, CA, United States; Lim, C.Y., GenentechSouth San Francisco, CA, United States; Shulman, N.S., GenentechSouth San Francisco, CA, United States; Yetzer, E.S., GenentechSouth San Francisco, CA, United States | |
dc.creator | Feld, J.J. | |
dc.creator | Jacobson, I.M. | |
dc.creator | Jensen, D.M. | |
dc.creator | Foster, G.R. | |
dc.creator | Pol, S. | |
dc.creator | Tam, E. | |
dc.creator | Jablkowski, M. | |
dc.creator | Berak, H. | |
dc.creator | Vierling, J.M. | |
dc.creator | Yoshida, E.M. | |
dc.creator | Perez-Gomez, H.R. | |
dc.creator | Scalori, A. | |
dc.creator | Hooper, G.J. | |
dc.creator | Tavel, J.A. | |
dc.creator | Navarro, M.T. | |
dc.creator | Shahdad, S. | |
dc.creator | Kulkarni, R. | |
dc.creator | Pogam, S.L. | |
dc.creator | Najera, I. | |
dc.creator | Eng, S. | |
dc.creator | Lim, C.Y. | |
dc.creator | Shulman, N.S. | |
dc.creator | Yetzer, E.S. | |
dc.date.accessioned | 2015-09-15T18:47:24Z | |
dc.date.accessioned | 2023-07-04T02:41:12Z | |
dc.date.available | 2015-09-15T18:47:24Z | |
dc.date.available | 2023-07-04T02:41:12Z | |
dc.date.created | 2015-09-15T18:47:24Z | |
dc.date.issued | 2015 | |
dc.identifier | http://hdl.handle.net/20.500.12104/44057 | |
dc.identifier | http://www.scopus.com/inward/record.url?eid=2-s2.0-24944547457&partnerID=40&md5=4bf246d3670ae4d80c0fa466596d847e | |
dc.identifier.uri | https://repositorioslatinoamericanos.uchile.cl/handle/2250/7262648 | |
dc.description.abstract | Background & Aims: Chronic hepatitis C treatment for prior non-responders to peginterferon (PegIFN)/ribavirin remains suboptimal. The MATTERHORN study evaluated regimens containing ritonavir-boosted danoprevir (danoprevir/r) in prior PegIFN alfa/ ribavirin non-responders. Methods: Prior partial responders (N = 152) were randomized to 24 weeks of twice-daily danoprevir/r 100/100 mg, mericitabine 1000 mg and ribavirin 1000/1200 mg (IFN-free); danoprevir/r plus PegIFN alfa-2a/ribavirin (triple); or danoprevir/r, mericitabine and PegIFN alfa-2a/ribavirin (Quad). Prior null responders (N = 229) were randomized to 24 weeks of IFN-free therapy, or quad alone (Quad 24) or quad plus 24-weeks of PegIFN alfa-2a/ ribavirin (Quad 48). The primary endpoint was sustained virological response (HCV RNA <25 IU/ml) 24 weeks after end-of-treatment (SVR24). Due to high relapse rates, genotype (G) 1a patients in IFN-free arms were offered additional PegIFN alfa-2a/ribavirin. Results: Among prior partial responders, SVR24 rates were 46.2%, 51.0%, and 86.0%, in the IFN-free, Triple and Quad arms, respectively; among prior null responders, SVR24 rates were 45.5%, 80.5%, and 83.8% respectively. Relapse rates were lower and SVR24 rates higher in G1b-infected than G1a-infected patients. SVR24 rates in G1a and G1b patients randomized to Quad were 75.0% and 96.2%, respectively, in the partial Quad arm, and 68.1% and 100%, respectively, in the null Quad 24 arm. Treatment failure was associated with resistance to danoprevir, but not to mericitabine, and was more common in G1a infected patients. Treatment was well-tolerated. Conclusions: Danoprevir/r, mericitabine plus PegIFN alfa-2a/ ribavirin was well-tolerated and produced high overall SVR24 rates in prior partial and null responders to PegIFN alfa/ribavirin. In contrast, IFN-free regimens were associated with unacceptably high relapse rates. " 2014 European Association for the Study of the Liver.",,,,,,,,,"http://hdl.handle.net/20.500.12104/44056","http://www.scopus.com/inward/record.url?eid=2-s2.0-84922250521&partnerID=40&md5=be123fe5b299625509a421ce7cdf4e76 | |
dc.description.abstract | http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medc&AN=25239078",,,,,,"2",,"Journal of Hepatology",,"294 | |
dc.description.abstract | 302",,"62",,"Scopus | |
dc.description.abstract | MEDLINE | |
dc.description.abstract | WOS",,,,"Index Medicus;Cytochrome P-450 CYP3A Inhibitors/ad [Administration & Dosage];Dose-Response Relationship, Drug;Drug Administration Schedule;Drug Carriers;Drug Therapy, Combination;Female;Follow-Up Studies;Genotype;Hepacivirus/ge [Genetics];Hepatitis C, Chronic/dt [Drug Therapy];Hepatitis C, Chronic/vi [Virology];Humans;Interferon-alpha/ad [Administration & Dosage];Lactams/ad [Administration & Dosage];Male;Middle Aged;Polyethylene Glycols/ad [Administration & Dosage];RNA, Viral/ge [Genetics];Recombinant Proteins/ad [Administration & Dosage];Retrospective Studies;Ribavirin/ad [Administration & Dosage];Ritonavir/ad [Administration & Dosage];Sulfonamides/ad [Administration & Dosage];Treatment Outcome",,"Danoprevir; Genotype 1; Mericitabine; Non-responders; Peginterferon/ribavirin; Quad therapy",,,,,,"Randomized study of danoprevir/ritonavir-based therapy for HCV genotype 1 patients with prior partial or null responses to peginterferon/ribavirin",,"Article"
"45886","123456789/35008","Flores-Soto, M.E., Laboratorio de Regeneración y Desarrollo Neural, Instituto de Neurobiología, Departamento de Biología Celular y Molecular, CUCBA, Mexico.; Chaparro-Huerta, V.; Escoto-Delgadillo, M.; Ureña-Guerrero, M.E.; Camins, A.; Beas-Zarate, C. | |
dc.description.abstract | Beas-Zárate, Carlos., Universidad de Guadalajara. Centro Universitario de Ciencias Biológicas y Agropecuarias",,"Flores-Soto, M.E. | |
dc.description.abstract | Chaparro-Huerta, V. | |
dc.description.abstract | Escoto-Delgadillo, M. | |
dc.description.abstract | Urena-Guerrero, M.E. | |
dc.description.abstract | Camins, A. | |
dc.description.abstract | Beas-Zárate, Carlos",,"2013",,"Glutamic acid (Glu) is the major excitatory neurotransmitter in the central nervous system, and interacts with two classes of receptor: metabotropic and ionotropic receptors. Ionotropic receptors are divided according to the affinity of their specific agonists: Nmethyl- D-aspartate (NMDA), amino acid-3-hydroxy-5-methyl-4-isoxazole acid (AMPA) and kainic acid (KA). NMDA receptors (NMDA-R) are macromolecular structures that are formed by different combinations of subunits: NMDAR1 (NR1), NMDAR2 (NR2) and NMDAR3 (NR3). The study of this receptor has aroused great interest, partly due to its role in synaptic plasticity but mainly because of its permeability to the Ca(2+) ion. This review examines the molecular composition of NMDA-R and the variants of NR1 subunit editing in association with NR2 subunit dimers, which form the main components of this receptor. Their composition, structure, function and distinct temporal and spatial expression patterns demonstrate the versatility and diversity of functionally different isoforms of NR1 subunits and the various pharmacological properties of the NR2 subunit. Finally, the involvement of NMDA-R in the excitotoxicity phenomenon, as well as, its expression changes under these conditions as neuronal response are also discussed.",,,,,,,,,,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84906289352&partnerID=40&md5=e1fecbcdf5e32c8ea0d35549b2b74195 | |
dc.description.abstract | http://hdl.handle.net/20.500.12104/44107",,,,,,"38",,"Current pharmaceutical design",,"6709 | |
dc.description.abstract | 6719",,"19",,"Scopus | |
dc.description.abstract | WOS",,,,,,,,,,"Receptor to glutamate NMDA-type: the functional diversity of the nr1 isoforms and pharmacological properties.",,,,"Article",
"45855","123456789/35008","Ovando-Medina, V.M., Centro de Investigación en Química Aplicada, Bulevar Enrique Reyna 140, Saltillo, Coahuila 25253, Mexico; Martínez-Gutiérrez, H., Centro de Investigación en Química Aplicada, Bulevar Enrique Reyna 140, Saltillo, Coahuila 25253, Mexico; Mendizábal, E., Departamento de Química, Centro Universitario de Ciencias Exactas e Ingenierías, Universidad de Guadalajara, Boulevard Marcelino García Barragán 1451, Guadalajara, Jalisco 44430, Mexico; Corona, M.A., Departamento de Química, Centro Universitario de Ciencias Exactas e Ingenierías, Universidad de Guadalajara, Boulevard Marcelino García Barragán 1451, Guadalajara, Jalisco 44430, Mexico; Peralta, R.D., Centro de Investigación en Química Aplicada, Bulevar Enrique Reyna 140, Saltillo, Coahuila 25253, Mexico, Departamento de Ingeniería Química, Coordinación Académica Región Altiplano (COARA), Universidad Autónoma de San Luis Potosí, Carretera a Cedral km 5+600, San José de las Trojes, Matehuala, SLP 78700, Mexico | |
dc.description.abstract | Mendizábal, E. M., Universidad de Guadalajara. Centro Universitario de Ciencias Exactas e Ingenierías",,"Ovando-Medina, V.M. | |
dc.description.abstract | Martinez-Gutierrez, H. | |
dc.description.abstract | Mendizábal, E. M. | |
dc.description.abstract | Corona, M.A. | |
dc.description.abstract | Peralta, R.D.",,"2009",,"The true monomer reactivity ratios for the vinyl acetate/butyl acrylate system were determined with experimental data from the cumulative copolymer composition at low, intermediate, and high conversions and with the monomer partitioning among the aqueous, microemulsion droplet, and polymer particle phases taken into account. A mixture of sodium dodecyl sulfate and poly(ethylene oxide) (23) dodecyl ether (Brij-35; 3 : 1 w/w) was used as a stabilizer. Potassium persulfate was used as an initiator. The true values of the monomer reactivity ratios were 0.028 ±3.2 × 10-3 for vinyl acetate and 6.219 ± 3.1 × 10-1 for butyl acrylate, and these were in agreement with those reported in the literature for bulk copolymerizations but differed from values reported for other compartmentalized copolymerizations. Thus, these results indicate that the monomer partitioning and cumulative copolymer composition throughout the reaction have to be duly accounted for in the determination of monomer reactivity ratios in heterogeneous polymerizations. © 2008 Wiley Periodicals, Inc.",,,,,,"10.1002/app.29041",,,,"http://www.scopus.com/inward/record.url?eid=2-s2.0-58149233853&partnerID=40&md5=d19cb04d51c3e5695c561972ada9a446 | |
dc.description.abstract | http://hdl.handle.net/20.500.12104/44076",,,,,,"1",,"Journal of Applied Polymer Science",,"329 | |
dc.description.abstract | 337",,"111",,"Scopus | |
dc.description.abstract | WOS",,,,,,"Copolymerization; Kinetics (polym.); Microstructure; Modeling; Radical polymerization",,,,"Reactivity ratios and monomer partitioning in the microemulsion copolymerization of vinyl acetate and butyl acrylate",,,,"Article",
"45846","123456789/35008","Mendizábal-Ruiz, A.P., Universidad de Guadalajara, Mexico; Morales, J., Universidad de Guadalajara, Mexico; Castro Martinez, X., Universidad de Guadalajara, Mexico, Centro Universitario de Ciencias de la Salud, Mexico; Gutierrez Rubio, S.A., Universidad de Guadalajara, Mexico; Valdez, L., University of Colima, Mexico; Vásquez-Camacho, J.G., Instituto Mexicano Del Seguro Social, Mexico, Hospital de Especialidades, Unidad de Anatomia Patológica, Mexico; Sanchez Corona, J., Instituto Mexicano Del Seguro Social, Mexico, Centro de Investigación, Biomédica de Occidente, División de Medicina, Molecular Sierra Mojada, 800 Guadalajara, Mexico; Moran Moguel, M.C., Centro de Investigación, Biomédica de Occidente, División de Medicina, Molecular Sierra Mojada, 800 Guadalajara, Mexico",,"Mendizábal-Ruiz, A.P. | |
dc.description.abstract | Morales, J. | |
dc.description.abstract | Castro Martinez, X. | |
dc.description.abstract | Gutierrez Rubio, S.A. | |
dc.description.abstract | Valdez, L. | |
dc.description.abstract | Vasquez-Camacho, J.G. | |
dc.description.abstract | Sanchez Corona, J. | |
dc.description.abstract | Moran Moguel, M.C.",,"2011",,"Recent information has revealed new roles in the angiogenic processes linked to the rennin-angiotensin system. To date few studies have been done on the association between RAS genes and cancer and the majority focus mainly on angiotensin I-converting enzyme (ACE). For breast cancer there are three reports that include the angiotensin II receptor, subtype 1 (AGTR1), only one for angiotensinogen (AGT) and none for renin gene (REN). In the present study we investigate whether REN (BglI), AGT (M235T), ACE (A245T, Indel), and AGTR1 (A1166C) are associated with breast cancer. Polymorphisms were analysed by PCR and RFPLs or sequence specific assay in three groups: breast cancer, benign breast disease (BBD) and general population. REN polymorphism shows that homozygous for A allele have an increased risk for BBD. Differences in M235T genotype frequencies were significant with less heterozygous in breast cancer. With different risk values ACE indel was associated with BBD and breast cancer. Association of AGTR1 was observed only in the breast cancer group, where C allele carriers present a reduced risk. Results of this work supports previous observations on the possible involvement of this system in breast cancer but it also suggests a role in benign disease. © The Author(s) 2010.",,,,,,"10.1177/1470320310383735",,,,"http://www.scopus.com/inward/record.url?eid=2-s2.0-79958069411&partnerID=40&md5=1692627e6c3b50722badeb9cb105a8ca | |
dc.description.abstract | http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=21109584 | |
dc.description.abstract | http://hdl.handle.net/20.500.12104/44067",,,,,,"2",,"JRAAS - Journal of the Renin-Angiotensin-Aldosterone System",,"85 | |
dc.description.abstract | 92",,"12",,"Scopus | |
dc.description.abstract | MEDLINE | |
dc.description.abstract | WOS",,,,"Index Medicus;Adult;Age Distribution;Aged;Alleles;Breast/cy [Cytology];Breast/me [Metabolism];Breast/pa [Pathology];Breast Neoplasms/ge [Genetics];Breast Neoplasms/pa [Pathology];Female;Gene Frequency/ge [Genetics];Haplotypes/ge [Genetics];Humans;Middle Aged;Polymorphism, Genetic;Renin-Angiotensin System/ge [Genetics]",,"ACE gene; AGT gene; AGT1R gene; benign breast disease; breast cancer; polymorphisms; REN gene; renin-angiotensin system",,,,"RAS polymorphisms in cancerous and benign breast tissue",,,,"Article",
"45860","123456789/35008",,,,"Gwiazdowski,Rodger A. | |
dc.description.abstract | Normark,Benjamin B.",,"2014",,,,,,,,"10.1021/la00086a017",,"0013-8746","http://hdl.handle.net/20.500.12104/44081","http://www.bioone.org/doi/abs/10.1603/AN13041",,,,"Entomological Society of America",,"2",,"Annals of the Entomological Society of America",,"356 | |
dc.description.abstract | 363",,"107",,"BioOne",,,,,,,,,,,,"An Unidentified Parasitoid Community (Chalcidoidea) is Associated with Pine-Feeding Chionaspis Scale Insects (Hemiptera: Diaspididae)",,"Journal Article"
"45853","123456789/35008",,"Ochoa-Guzmán, A., Servicio de Neurología, Hospital Civil de Guadalajara Fray Antonio Alcalde, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico; Chiquete, E., Servicio de Medicina Interna, Hospital Civil de Guadalajara Fray Antonio Alcalde, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico, Departamento de Clínicas Médicas, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico; Navarro-Bonnet, J., Servicio de Neurología, Hospital Civil de Guadalajara Fray Antonio Alcalde, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico; Gutiérrez-Plascencia, P., Servicio de Neurología, Hospital Civil de Guadalajara Fray Antonio Alcalde, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico; Zúñiga-Ramírez, C., Servicio de Neurología, Hospital Civil de Guadalajara Fray Antonio Alcalde, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico; Ruiz-Sandoval, J.L., Servicio de Neurología, Hospital Civil de Guadalajara Fray Antonio Alcalde, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico, Departamento de Neurociencias, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico",,"Ochoa-Guzman, A. | |
dc.description.abstract | Chiquete, E. | |
dc.description.abstract | Navarro-Bonnet, J. | |
dc.description.abstract | Gutierrez-Plascencia, P. | |
dc.description.abstract | Zuniga-Ramirez, C. | |
dc.description.abstract | Ruiz-Sandoval, J.L.",,"2011",,"[No abstract available]",,,,,,,,,"http://hdl.handle.net/20.500.12104/44074","http://www.scopus.com/inward/record.url?eid=2-s2.0-79952203026&partnerID=40&md5=24c9ce467840a941e9ab1d73c98208f7",,,,,,"2",,"Revista de Neurologia",,"125 | |
dc.description.abstract | 126",,"52",,"Scopus | |
dc.description.abstract | WOS",,,,,,,,,,,,"Reactivation of herpes zoster after electrocution [Reactivación de herpes zóster por electrocución]",,"Letter"
"45836","123456789/35008",,"López-Uriarte, E., Laboratorio de Ecosistemas Marinos Y Acuicultura, Departamento de Ecología, Universidad de Guadalajara, Apartado Postal 52-114, Zapopan 45030, Jalisco, Mexico; Ríos-Jara, E., Laboratorio de Ecosistemas Marinos Y Acuicultura, Departamento de Ecología, Universidad de Guadalajara, Apartado Postal 52-114, Zapopan 45030, Jalisco, Mexico; Pérez-Peña, M., Laboratorio de Ecosistemas Marinos Y Acuicultura, Departamento de Ecología, Universidad de Guadalajara, Apartado Postal 52-114, Zapopan 45030, Jalisco, Mexico",,"Lopez-Uriarte, E. | |
dc.description.abstract | Rios-Jara, E. | |
dc.description.abstract | Perez-Pena, M.",,"2005",,"Hubbs' octopus Octopus hubbsorum Berry, 1953 is reported at 24 localities along the Pacific coast of Mexico. The distribution of the species, previously recorded in the Gulf of California (28°55'N, 113°32'W) and in Melaque (southern coast of Jalisco) (19 degree 12'N, 105 degree 40'W), is extended south to Salina Cruz, Oaxaca (16°10'N, 95°14'W). Specimens were captured in the intertidal and subtidal zones to depths of 30 m. This is the principal target species in the octopus fisheries of this vast region. " 2005 Rosenstiel School of Marine and Atmospheric Science of the University of Miami. | |
dc.relation | Scopus | |
dc.relation | WOS | |
dc.relation | Bulletin of Marine Science | |
dc.relation | 77 | |
dc.relation | 2 | |
dc.relation | 171 | |
dc.relation | 175 | |
dc.title | Range extension for Octopus hubbsorum (Mollusca: Octopodidae) in the Mexican pacific | |
dc.type | Article | |